Xerostomia: Selected Treatments
Customize your policy alerts
Sign up for Aetna Policy 0302 alerts
Get alerted when Policy 0302 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for selected non-pharmacologic and device-based treatments for xerostomia (dry mouth) for Aetna members. It identifies interventions considered experimental/investigational and lists related billing codes and clinical background evidence summaries.
No material clinical or coverage changes in this revision.
Coverage Criteria — Experimental / Investigational Interventions
inv-01: Experimental and Investigational
The following interventions are considered experimental and investigational because effectiveness has not been established:
List is not all-inclusive
inv-02: Evidence synthesis for coverage considerations
Summary of evidence-based findings relevant to coverage decisions
Chunks: 20,21,24,25,37
Chunks: 18,22,29
Chunks: 34,35
Chunks: 39
Chunks: 27,49,42
inv-03: Evidence summaries relevant to coverage
Evidence summaries and implications for coverage decisions:
Chunks: 42,44
Chunks: 42,44,49
Chunks: 35,34
Chunks: 37,25
Chunks: 42,27,49
Certain CPT, HCPCS and ICD-10 codes are specifically enumerated in this Clinical Policy Bulletin as not covered for the indications listed in the CPB. Providers should verify medical necessity and coverage prior to performing or billing these services, since submission of these codes for the CPB-listed indications may result in claim denials.
Fat grafting to salivary glands is described in the literature as a preclinical or early translational approach: co-culture and animal transplantation studies demonstrate differentiation of adipose-derived stem cells into salivary-gland-like tissue, but clinical evidence is absent and major clinical resources (including a systematic review and an UpToDate review) do not list fat grafting as a therapeutic option. Therefore this technique remains experimental and not established for routine patient care.
Systematic reviews and evidence summaries found insufficient evidence to determine the effects of numerous interventions (for example, biperiden plus pilocarpine, various Chinese medicines, bethanechol, artificial saliva as a disease‑modifying therapy, selenium, antiseptic mouth rinses, antimicrobial lozenges, polaprezinc, azulene rinse, and Venalot Depot). These therapies remain investigational pending higher-quality data.
This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is intended to assist in administering benefits. It is not a contract, does not constitute medical advice, and may be updated; providers should consult the full policy and plan documents for definitive coverage and authorization requirements.
Interventions explicitly listed as experimental and investigational in this bulletin are considered not established for effectiveness. As a result, these interventions are regarded as not medically necessary for the prevention or treatment of xerostomia for the indications covered by this CPB.
Systematic reviews and randomized trials evaluating transcutaneous electrical nerve stimulation (TENS/ALTENS) and related electrical stimulation approaches show heterogeneous results. A pooled analysis of six RCTs (369 participants) did not demonstrate a statistically significant benefit for TENS on salivary flow, and photo‑biomodulation (LLLT) trials and meta-analyses report short‑term increases in salivary flow but with high risk of bias and heterogeneity. Overall, the evidence lacks consistent, high‑quality demonstration of clinical benefit for electrical stimulation or related modalities.
A single randomized trial of intravenous amifostine closed early and was underpowered; it did not show a clear reduction in grade ≥2 xerostomia and was associated with higher rates of other toxicities (for example, increased vomiting, hypotension and fatigue). Given the limited sample size and increased non‑xerostomia adverse effects, this study does not provide definitive support for routine use of intravenous amifostine to prevent radiotherapy‑induced xerostomia.
Billing and Coding
| 0552T | Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional. |
| 15769 | Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia). |
| 15773 | Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate. |
| 15774 | Each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure). |
| 97810 | Acupuncture. |
| 97811 | Acupuncture. |
| 97812 | Acupuncture. |
| 97813 | Acupuncture. |
| 97814 | Acupuncture. |
| 99183 | Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session. |
| K11.7 | Disturbance of salivary secretion (xerostomia). |
| R68.2 | Dry mouth, unspecified. |
| T66.xx | Effects of radiation, unspecified [radiation-induced xerostomia]. |
| Z92.3 | Personal history of irradiation. |
Provider Actions, Prior Authorization, and Documentation
Evidence incompleteness may affect coverage
Evidence incompleteness may affect coverage decisions. Several trials (for example, RTOG 0537) had limited evaluable populations, incomplete data, or preliminary small-phase results; providers should be aware that such limitations can influence medical necessity determinations and coverage.
- Incomplete or underpowered trials may lead to noncoverage or experimental classification.
- When relying on trial evidence for novel therapies (e.g., ASC transplantation, amifostine), document trial limitations in the medical record.
Suggested objective measures for documentation
Use objective, standardized measures to document salivary function when clinically assessing xerostomia and when requesting coverage for treatments. Preferred measures in the literature include unstimulated and stimulated whole saliva flow rates collected with timed, graduated collection methods.
- Unstimulated whole saliva (e.g., 5–10 minute low forced spitting method) with reported ml/min.
- Stimulated whole saliva collection (e.g., electrical or citric acid stimulation) with reported ml/min.
- Report collection method, timing relative to radiation or intervention, and baseline vs post-treatment values.
Required clinical outcome documentation for experimental therapies
When experimental or investigational therapies are used (for example, stem cell transplantation, investigational pharmacologic agents, or procedures without established coding), clinical outcome documentation should include validated patient-reported outcomes and objective salivary measures, and report adverse events. Trial-reported outcome domains commonly include unstimulated/stimulated saliva flow, xerostomia questionnaires (e.g., XeQOLS), VAS for symptoms, and gland function assays.
- Include baseline and serial post-treatment measurements (specify timepoints).
- Include patient-reported xerostomia scales (e.g., XeQOLS) and symptom VAS scores.
- Document any procedure- or drug-related adverse events and biopsy/imaging findings if obtained.
Documentation note and administrative guidance
Refer to the full clinical policy bulletin for complete documentation requirements, coding guidance, and supplemental information. The excerpt does not specify prior authorization rules or step therapy in this portion; providers should verify plan-specific authorization and coding prior to billing.
- Verify member benefits and prior authorization requirements with the payer before performing procedures.
- Consult the full CPB for lists of CPT/HCPCS/ICD-10 codes noted as not covered for listed indications.
- Maintain complete clinical records supporting medical necessity, including objective measures and trial rationale when applicable.
No step therapy rules included in this extract
No step therapy rules are specified in the provided policy extract. There are no step-therapy sequences or mandatory conservative-first pathways stated here; however, conservative measures (salivary substitutes, sips of water, conventional pharmacologic agents) are commonly used first-line in practice before experimental or invasive interventions.
- If a plan requires conservative therapy trials, document dates, agents used (e.g., salivary substitutes, pilocarpine), durations, and clinical response.
- Absence of step therapy in this extract does not preclude plan-level or benefit-specific requirements; verify per member plan.
Background and Context
Chronic xerostomia may result from autoimmune disease (for example, Sjögren's syndrome), medications, or therapeutic irradiation. It can cause difficulty with eating, swallowing and denture use, and it increases risk for dental caries, oral pain and infections. Management focuses on symptomatic relief (saliva substitutes, stimulants) and, for investigational regenerative or device‑based therapies, the evidence base remains limited; these factors inform the experimental/investigational designations in this bulletin.
Definitions and Terminology
Policy Dates and Revision History
Policy became effective.
Policy was last reviewed.
Next policy review scheduled.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.